Synonym
Zalunfiban acetate; RUC-4 acetate; Zalunfiban acetate [USAN]; 722PY2DT28; UNII-722PY2DT28;
IUPAC/Chemical Name
acetic acid;2-amino-N-[5-(5-oxo-7-piperazin-1-yl-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)pyridin-3-yl]acetamide
InChi Key
UJGNATZMWUYIRZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H18N8O2S.C2H4O2/c17-7-13(25)20-11-5-10(8-19-9-11)15-22-24-14(26)6-12(21-16(24)27-15)23-3-1-18-2-4-23;1-2(3)4/h5-6,8-9,18H,1-4,7,17H2,(H,20,25);1H3,(H,3,4)
SMILES Code
CC(O)=O.O=C(NC1=CC(C(S2)=NN(C2=NC(N3CCNCC3)=C4)C4=O)=CN=C1)CN
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
446.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Rikken SAOF, Bor WL, Selvarajah A, Zheng KL, Hack AP, Gibson CM, Granger CB,
Bentur OS, Coller BS, van 't Hof AWJ, Ten Berg JM. Prepercutaneous coronary
intervention Zalunfiban dose-response relationship to target vessel blood flow
at initial angiogram in st-elevation myocardial infarction - A post hoc analysis
of the cel-02 phase IIa study. Am Heart J. 2023 Aug;262:75-82. doi:
10.1016/j.ahj.2023.04.009. Epub 2023 Apr 22. PMID: 37088164.
2: Rikken SAOF, Selvarajah A, Hermanides RS, Coller BS, Gibson CM, Granger CB,
Lapostolle F, Postma S, van de Wetering H, van Vliet RCW, Montalescot G, Ten
Berg JM, van 't Hof AWJ; CELEBRATE investigators. Prehospital treatment with
zalunfiban (RUC-4) in patients with ST- elevation myocardial infarction
undergoing primary percutaneous coronary intervention: Rationale and design of
the CELEBRATE trial. Am Heart J. 2023 Apr;258:119-128. doi:
10.1016/j.ahj.2022.12.015. Epub 2022 Dec 31. PMID: 36592878.
3: Rikken SAOF, Storey RF, Andreotti F, Clemmensen P, Ten Berg JM. Parenteral
Antiplatelet Drugs in ST-Elevation Myocardial Infarction: Current Status and
Future Directions. Thromb Haemost. 2023 Feb;123(2):150-158. doi:
10.1055/s-0042-1753479. Epub 2022 Sep 8. PMID: 36075236.
